On Friday, Processa Pharmaceuticals Inc (NASDAQ: PCSA) opened higher 8.80% from the last session, before settling in for the closing price of $0.31. Price fluctuations for PCSA have ranged from $0.24 to $3.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 75.19% at the time writing. With a float of $4.67 million, this company’s outstanding shares have now reached $5.27 million.
Let’s look at the performance matrix of the company that is accounted for 10 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Processa Pharmaceuticals Inc (PCSA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Processa Pharmaceuticals Inc is 11.36%, while institutional ownership is 1.88%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.65% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Check out the current performance indicators for Processa Pharmaceuticals Inc (PCSA). In the past quarter, the stock posted a quick ratio of 1.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.89, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Processa Pharmaceuticals Inc (NASDAQ: PCSA) saw its 5-day average volume 11.3 million, a positive change from its year-to-date volume of 1.09 million. As of the previous 9 days, the stock’s Stochastic %D was 31.28%. Additionally, its Average True Range was 0.07.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 7.94%, which indicates a significant decrease from 40.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 152.61% in the past 14 days, which was higher than the 101.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5134, while its 200-day Moving Average is $1.1300. Nevertheless, the first resistance level for the watch stands at $0.3760 in the near term. At $0.4119, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4592. If the price goes on to break the first support level at $0.2928, it is likely to go to the next support level at $0.2455. Assuming the price breaks the second support level, the third support level stands at $0.2096.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
There are currently 5,269K shares outstanding in the company with a market cap of 1.79 million. Presently, the company’s annual sales total 0 K according to its annual income of -11,850 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -2,730 K.
